Molecular Insight Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Boston MA United States (1997)
Status: Acquired by Progenics (2013) → now Lantheus Medical Imaging (2019)

Organization Overview

First Clinical Trial
2006
NCT00339131
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Molecular Insight Pharmaceutical Employee | Molecular Insight Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 2)

Adenocarcinoma (Phase 1)

Carcinoid Tumor (Phase 2)

Carotid Body Tumor (Phase 2)

Melanoma (Phase 1)

Neuroblastoma (Phase 2)

Neuroendocrine Tumors (Phase 2)

Paraganglioma (Phase 2)

Pheochromocytoma (Phase 2)

Prostatic Neoplasms (Phase 3)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 10